Speech-Language Pathologists in Neillsville, WI Accepting Medicare

2 Speech-Language Pathologists found. Showing 1 - 2

Barbara L Colba, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 517 Court St Rm 503, Neillsville, WI 54456 Phone: 715-743-5192    Fax: 715-743-5209

Mrs. Ann Marie Stallons, MS-CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 216 Sunset Pl, Neillsville, WI 54456 Phone: 715-743-3101    Fax: 715-743-6242

News Archive

Biologists show bioelectrical signals control tumors arising from cancer-causing genes, fatty acid

Developmental biologists at Tufts University, using a tadpole model, have shown that bioelectrical signals from distant cells control the incidence of tumors arising from cancer-causing genes and that this process is impacted by levels of a common fatty acid produced by bacteria found in the tadpole and also in humans.

CryoLife files emergency motion for preliminary injunction against Medafor

CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it filed an emergency motion for a preliminary injunction against Medafor, Inc. in the United States District Court for the Northern District of Georgia, Atlanta division. CryoLife contends that Medafor is improperly attempting to terminate the exclusive distribution agreement ("EDA") between the parties, and CryoLife has requested that the Court enjoin Medafor from proceeding with the termination.

Zebrafish research may help determine what causes certain birth defects

Description of dozens of mutations that will help determine the earliest steps in vertebrate development, which take the spherical embryo to a complex creature

Stryker Corporation to acquire all assets of Small Bone Innovations for $375M

Small Bone Innovations, Inc. (SBi) today announced that Stryker Corporation will acquire substantially all the assets of SBi in an all cash transaction for up to $375 million.

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

Read more Medical News

› Verified 6 days ago